341 related articles for article (PubMed ID: 31052488)
1. Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review.
Chicas-Sett R; Morales-Orue I; Castilla-Martinez J; Zafra-Martin J; Kannemann A; Blanco J; Lloret M; Lara PC
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052488
[No Abstract] [Full Text] [Related]
2. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
Lieverse RIY; Van Limbergen EJ; Oberije CJG; Troost EGC; Hadrup SR; Dingemans AC; Hendriks LEL; Eckert F; Hiley C; Dooms C; Lievens Y; de Jong MC; Bussink J; Geets X; Valentini V; Elia G; Neri D; Billiet C; Abdollahi A; Pasquier D; Boisselier P; Yaromina A; De Ruysscher D; Dubois LJ; Lambin P
BMC Cancer; 2020 Jun; 20(1):557. PubMed ID: 32539805
[TBL] [Abstract][Full Text] [Related]
3. Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer.
Zafra J; Onieva JL; Oliver J; Garrido-Barros M; González-Hernández A; Martínez-Gálvez B; Román A; Ordóñez-Marmolejo R; Pérez-Ruiz E; Benítez JC; Mesas A; Vera A; Chicas-Sett R; Rueda-Domínguez A; Barragán I
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674117
[TBL] [Abstract][Full Text] [Related]
4. Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b Trial.
Bassetti MF; Morris BA; Sethakorn N; Lang JM; Schehr JL; Zhao SG; Morris ZS; Buehler D; Eickhoff JC; Harari PM; Traynor AM; Campbell TC; Baschnagel AM; Leal TA
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1481-1489. PubMed ID: 38072321
[TBL] [Abstract][Full Text] [Related]
5. Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial.
Monjazeb AM; Daly ME; Luxardi G; Maverakis E; Merleev AA; Marusina AI; Borowsky A; Mirhadi A; Shiao SL; Beckett L; Chen S; Eastham D; Li T; Vick LV; McGee HM; Lara F; Garcia L; Morris LA; Canter RJ; Riess JW; Schalper KA; Murphy WJ; Kelly K
Nat Commun; 2023 Sep; 14(1):5332. PubMed ID: 37658083
[TBL] [Abstract][Full Text] [Related]
6. Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review.
Chicas-Sett R; Morales-Orue I; Rodriguez-Abreu D; Lara-Jimenez P
Clin Transl Radiat Oncol; 2018 Feb; 9():5-11. PubMed ID: 29594244
[TBL] [Abstract][Full Text] [Related]
7. Three discipline collaborative radiation therapy (3DCRT) special debate: The single most important factor in determining the future of SBRT is immune response.
Grassberger C; Huber K; Jacob NK; Green MD; Mahler P; Prisciandaro J; Dominello M; Joiner MC; Burmeister J
J Appl Clin Med Phys; 2019 Oct; 20(10):6-12. PubMed ID: 31573143
[No Abstract] [Full Text] [Related]
8. Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective stud.
Voong KR; Illei PB; Presson B; Singh D; Zeng Z; Lanis M; Hales RK; Hu C; Tran PT; Georgiades C; Lin CT; Thiboutout J; Brahmer JR; Forde PM; Naidoo J; Anagnostou V; Smith KN
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793854
[TBL] [Abstract][Full Text] [Related]
9. Concomitant Irradiation to Checkpoint Inhibitor Therapy of Hepatocellular Carcinoma Patients: A Systematic Retrospective, Single-Center Analysis.
Munker S; Roessler D; Öcal O; Ben-Khaled N; Bernhart K; Ye L; Piseddu I; Vielhauer J; Reiter FP; Rodriguez I; Ricke J; Teufel A; De Toni E; Seidensticker M; Niyazi M; Corradini S
Oncol Res Treat; 2023; 46(11):466-475. PubMed ID: 37827135
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Antiangiogenic Agents.
Lau BC; Wu YF; No HJ; Ko RB; Devine MD; Das MS; Neal JW; Wakelee HA; Ramchandran K; Gensheimer MF; Diehn M; Chin AL; Loo BW; Vitzthum LK
J Thorac Oncol; 2023 Jul; 18(7):922-930. PubMed ID: 37085030
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy with or without immunotherapy in metastatic melanoma: efficacy and tolerability.
Backlund E; Grozman V; Egyhazi Brage S; Lewensohn R; Lindberg K; Helgadottir H
Acta Oncol; 2023 Dec; 62(12):1921-1930. PubMed ID: 37966921
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic ablative radiotherapy and FAPα-based cancer vaccine suppresses metastatic tumor growth in 4T1 mouse breast cancer.
Chen M; Xiao L; Jia H; Wang S; Jiang X; Lei X; Zhai Q; Lang J
Radiother Oncol; 2023 Dec; 189():109946. PubMed ID: 37806560
[TBL] [Abstract][Full Text] [Related]
13. Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists.
Li S; Shen L
J Cancer; 2020; 11(17):5056-5068. PubMed ID: 32742453
[TBL] [Abstract][Full Text] [Related]
14. Abscopal effect in maxillary sinus cancer: Insights from two case reports and a literature review.
Sakai A; Ebisumoto K; Iijima H; Yamauchi M; Maki D; Fukuzawa T; Okami K
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1994. PubMed ID: 38351554
[TBL] [Abstract][Full Text] [Related]
15. Reconciling the discrepancies in randomized data of combining immunotherapy and radiation therapy: Not all radiotherapy is created equal.
Chang JY; Verma V; Weichselbaum RR
Eur J Cancer; 2024 Apr; 201():113972. PubMed ID: 38430868
[TBL] [Abstract][Full Text] [Related]
16. A Case of Success With Immunotherapy After Changing the Therapeutics Strategy in Non-small Cell Lung Cancer.
Machado B; Soares de Pinho I; Aranha AR; Malyarchuck V; Godinho J
Cureus; 2023 Oct; 15(10):e47874. PubMed ID: 38021550
[TBL] [Abstract][Full Text] [Related]
17. Combination radiation and immunotherapy in gynecologic malignancies-a comprehensive review.
Ladbury C; Germino E; Novak J; Liu J; Horne Z; Dyer B; Glaser S
Transl Cancer Res; 2021 May; 10(5):2609-2619. PubMed ID: 35116574
[TBL] [Abstract][Full Text] [Related]
18. Impact of Waiting Response Evaluation to First-Line Systemic Therapy before Considering Local Ablative Therapy in Metastatic Non-Small-Cell Lung Cancer.
Belaidi L; Wang P; Quintin K; Durdux C; Giroux-Leprieur E; Giraud P
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958302
[TBL] [Abstract][Full Text] [Related]
19. Editorial: Immunotherapy and multimodality therapy for lung cancer.
Song C; Liu W; Wan Y; Mao W
Front Immunol; 2024; 15():1372513. PubMed ID: 38343541
[No Abstract] [Full Text] [Related]
20. Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors.
Mundra V; Yang Y; von Itzstein MS; Fattah F; Gonugunta AS; Hannan R; Pop LM; Zhang Y; Wang Y; Sheffield T; Xie Y; Dowell JE; Homsi J; Rashdan S; Park J; Li QZ; Wakeland EK; Gerber DE
Transl Oncol; 2023 Aug; 34():101689. PubMed ID: 37285748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
